BIOMACS II

BIOMACS II

Biochemical Markers in Acute Coronary Syndromes. A pilot trial that evaluated the effect of a low-molecular weight heparin (dalteparin), as an adjuvant to thrombolysis in patients with acute MI.
 
Primary endpoints
Proportion of patients with successful reperfusion, recurrent ischemia, patency at 24 hours.

Conclusion
Dalteparin added to streptokinase tended to provide a higher rate of TIMI grade-3 flow in infarct-related artery compared with placebo; there were also fewer recurrent ischaemic episodes 6 to 24 hours after treatment, per Holter monitoring in the dalteparin group.

Logistics
Randomised, placebo-controlled; 101 patients, dalteparin or placebo given just before streptokinase; a second injection of dalteparin or placebo was administered 12 hours after the initial dose.